Table 6

MCII and participant responders based on changes between baseline and 8 weeks and between baseline and 6 months

Number with MCII (%)

Variables

Pearson's χ²

P values

OAK

Control

Preintervention to 8 weeks

WOMAC Physical Function, absolute

10.84_{(1, 141)}

P = 0.001

25 (37%)

9 (13%)

WOMAC Physical Function (%)

19.34_{(1, 141)}

P ≤ 0.001

29 (43%)

7 (10%)

SF-36 Physical Function

8.34_{(1, 140)}

P = 0.006

40 (60%)

23 (34%)

SF-36 Pain

1.38_{(1, 139)}

P = 0.265

23 (34%)

17 (25%)

VAS Pain, absolute

15.95_{(1, 139)}

P ≤ 0.001

27 (40%)

7 (10%)

VAS Pain (%)

17.37_{(1, 139)}

P ≤ 0.001

25 (37%)

5 (7%)

TUG

28.87_{(1, 139)}

P ≤ 0.001

46 (69%)

15 (22%)

Responders

13.59_{(1, 141)}

P ≤ 0.001

26 (39%)^b

8 (12%)^b

Preintervention to 6 months

WOMAC Physical Function, absolute

3.87_{(1, 135)}

P = 0.057

24 (14%)

14 (20%)

WOMAC Physical Function (%)

4.37_{(1, 135)}

P = 0.043

27 (40%)

15 (22%)

SF-36 Physical Function

2.93_{(1, 136)}

P = 0.122

40 (60%)

29 (43%)

SF-36 Pain

0.95_{(1, 135)}

P = 0.384

31 (46%)

25 (37%)

TUG

5.10_{(1, 132)}

P = 0.036

38 (57%)

26 (38%)

Responders

2.58_{(1, 135)}

P = 0.123

22 (33%)^b

14 (20%)^b

^aMCII: minimal clinically important improvement; OARSI: Osteoarthritis Research International; OMERACT: Outcome Measures in Rheumatology; SF-36: Short Form 36 version 1 questionnaire; TUG: Timed Up & Go Test; VAS: Visual Analogue Scale; WOMAC: Western Ontario and McMaster Universities Arthritis Index. ^bData are number of responders based on the OMERACT-OARSI criteria [46].

Coleman et al. Arthritis Research & Therapy 2012 14:R21   doi:10.1186/ar3703